The document discusses current FDA-approved drugs for treating Alzheimer's disease symptoms like memantine (Namenda), as well as potential new treatments like CUBX, a hybrid drug that could act on both extracellular amyloid plaques and intracellular neurofibrillary tangles. It also mentions the large and growing societal costs of Alzheimer's care and the need to identify preventative strategies with no current cure available.

1. Dr. Barnes, there is currently no cure for AD and no disease-modifying
treatment, so the current best hope lies in identifying prevention strategies.
We believe our formulation will help
By 2050, as many as 16 million Americans will have
Alzheimer's and the cost of care will surpass $1
trillion annually."

2. The food and drug administration (FDA) has approved two drugs specifically to treat
symptoms of alzheimer's disease.
Cholinesterase inhibitors
Memantine
Sold under the brand namenda by forest laboratories inc and germany's merz
pharma, the drug had U.S.A Sales of about $1.2 billion last year.
For the study, researchers culled through published studies, presentations at medical
meetings and other sources to find studies that looked at the effectiveness of the drug
memantine, namenda's generic form, in patients with mild alzheimer's disease.
They found that memantine worked no better than a dummy pill at treating the
disease.

3. AB1-40
Under the microscope, there were widespread fatty deposits
in small blood vessels, dead and dying brain cells, and
abnormal protein amyloid deposits in and around cells.

4. Act on Extracellular neuritic amyloid plaques
Act on intracellular neurofibrillary tangles
Act as cholinesterase inhibitor

5. 
The value of the Alzheimer’s disease market across the
seven major markets was $4.7bn in 2009 and is forecast to
reach $11.9bn by 2019. Future market growth is set to be
driven by the first disease-modifying drugs, given their
significant price premium, likely therapeutic role as an
adjunctive and potential utility in prodromal Alzheimer's
diseaseDatamonitor forecasts that the current late-stage
pipeline will yield three blockbusters, but this is by no
means guaranteed considering the high risk of failure in
Phase III Alzheimer’s disease trials. Of the pipeline
drugs, Datamonitor believes that bapineuzumab and
solanezumab have the most commercial and clinical
potential.Datamonitor expects the symptomatic market will
remain active in this disease. New symptomatic entrants to
the market will include Aricept patch and the first-in-class
5-HT6 receptor antagonist SB-742457.

6. Worldwide, there are over 1000 published animal and human studies, both in vivo and in vitro in
which the effects of curcumin on various diseases have been examined. Studies include
epidemiological, basic and clinical research on AD.

7. 




We took advantage of existing knowledge of
curcumin and literature associated with its
limitations.
The biggest limitation is its solubility and
hence the absorption when consumed orally.
Stability is another issue
CUBX has curcumin properties in it
Our Hybrid Drug works Synergistically for two
pathological hallmark of AD i.e extracellular
neuritic amyloid plaques and intracellular
neurofibrillary tangles.

8. 



We resolved the issue of solubility and stability
of it
Our CUBXZIL molecule is soluble in water
Our CUBXZIL is not altered by any chemical
Our CUBXZIL is stable

9. Progressive Stages of Alzheimer’s Disease
Stage 1. ( Early or Mild):






Short term memory problems
May be unable to find the right words
Forgets familiar names and telephone numbers
Begins to write reminders but loses notes
Shows preference for familiar things
(Wears the same clothes, Avoids going out)
Judgment may be impaired
(May dress inappropriately for the weather)
We must try this drug to avoid progression

10. Progressive Stages of Alzheimer’s Disease
Stage 2a. (Middle or Moderate)):




Deterioration of ability to initiate and sequence
purposeful activities like bathing and driving
Sleep disturbance with restlessness at night
Begins to neglect health and hygiene
Needs directions to function in familiar
surroundings
We must try this drug to avoid progression

11. Progressive Stages of Alzheimer’s Disease
Stage 2b. (Middle or Moderate)






May lose ability to perform daily skills
(like buttoning a shirt or using a knife & fork)
May need to be told each step of a former routine act
(like brushing teeth or getting dressed)
May walk with a shuffling gait or may seem “glued to
the floor” due to a physical inability to walk
Often needs physical assistance with activities of
daily living (dressing, bathing, eating)
Needs protection and supervision
May lose the ability to read or write

12. Progressive Stages of Alzheimer’s Disease
Stage 3. (Late or Final):









Can’t walk
May discontinue talking or be unable to talk
Trouble swallowing
May have seizures
Incontinence
May make loud unintelligible negative noises or
sounds
Complete withdrawal or apathy
May lose control of outer extremities
Unable to survive without total care
WE MUST ACT BEFORE THIS

13. Alzheimer’s is the fifth leading cause of
disease death in the U.S.
Our molecule is really affordable to use. It
is safe and is reported to help.
Become part of the solution and bring
an end to this devastating disease!
I will be really be glad even if I would able to
contribute a little

14. 
























Generic Brand Approved For and Side Effects
donepezil
Aricept
All stages
Nausea, vomiting, loss of appetite and increased frequency of bowel movements.
galantamine
Razadyne
Mild to moderate
Nausea, vomiting, loss of appetite and increased frequency of bowel movements.
memantine
Namenda
Moderate to severe
Headache, constipation, confusion and dizziness.
rivastigmine
Exelon
Mild to moderate
Nausea, vomiting, loss of appetite and increased frequency of bowel movements.
tacrine
Cognex
Mild to moderate
Possible liver damage, nausea, and vomiting.
vitamin E
Not applicable
Not approved
Can interact with medications prescribed to lower cholesterol or prevent blood clots; may slightly increase risk of death.

15. At this point we can not
disclose the full and
final information about
our nanomedicine
compound drug.

16. 


Since ours is showing great results for arthritis
and cancer.
Our is not formulated in any kind of protein
Our is more stable and more potent
It is safe and we are looking for clinical
collaboration.
Doctors, organizations or community help

17. 


To treat inflammation
To treat stress
To treat cholinesterase inhibitor

19. Dr. Mewa Singh
mewasinghsandhu@hotmail.com
www.nanomeda.com
www.nanosgroup.com
LAETC, LSU Campus
Baton Rouge, LA
